NCT05250245View on ClinicalTrials.gov

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 30, 2021

Study Completion Date

January 1, 2022

Conditions
Overactive BladderObstructive Sleep ApneaOveractive Bladder Syndrome
Interventions
DRUG

Tolterodine Tartrate 4 MG

Tolterodine is actively being used in the treatment of over active bladder symptoms today

OTHER

Continuous positive airway pressure therapy (CPAP)

The gold standard for the treatment of confirmed OSAS is continuous positive airway pressure (CPAP) therapy

Trial Locations (1)

Unknown

Yuzuncu Yıl University, Van

All Listed Sponsors
lead

Yuzuncu Yıl University

OTHER

NCT05250245 - Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome | Biotech Hunter | Biotech Hunter